High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
| Autor: | Serge Leyvraz, Salvatore Siena, K. M. Champion, Jean Pierre Lotz, Paolo Pedrazzoli, Frédéric Selle, Giovanni Rosti, Simona Secondino, Jonathan A. Ledermann, Giovanni Grignani, Taner Demirer, Massimo Aglietta, N. Ketterer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Hematopoietic stem cell transplantation Breast cancer Internal medicine Neoplasms Medicine Humans Carcinoma Small Cell Ovarian Neoplasms Salvage Therapy Chemotherapy Dose-Response Relationship Drug business.industry Carcinoma Hematopoietic Stem Cell Transplantation Sarcoma Hematology Neoplasms Germ Cell and Embryonal medicine.disease Prognosis Chemotherapy regimen Combined Modality Therapy Surgery Female Germ cell tumors Stem cell business Ovarian cancer |
| Popis: | Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies. As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient. In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease. In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|